Mark A. Varney

5.7k total citations · 1 hit paper
85 papers, 4.6k citations indexed

About

Mark A. Varney is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Cognitive Neuroscience. According to data from OpenAlex, Mark A. Varney has authored 85 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Cellular and Molecular Neuroscience, 45 papers in Molecular Biology and 13 papers in Cognitive Neuroscience. Recurrent topics in Mark A. Varney's work include Neuroscience and Neuropharmacology Research (60 papers), Receptor Mechanisms and Signaling (31 papers) and Neurotransmitter Receptor Influence on Behavior (23 papers). Mark A. Varney is often cited by papers focused on Neuroscience and Neuropharmacology Research (60 papers), Receptor Mechanisms and Signaling (31 papers) and Neurotransmitter Receptor Influence on Behavior (23 papers). Mark A. Varney collaborates with scholars based in United States, United Kingdom and Netherlands. Mark A. Varney's co-authors include Linda J. Bristow, Sara Rao, Nicholas D. P. Cosford, Adrian Newman‐Tancredi, Jesse Brodkin, Daniel S. Lorrain, Edwin C. Johnson, Christopher Baccei, Lida Tehrani and Stephen D. Hess and has published in prestigious journals such as The Journal of Comparative Neurology, Analytical Biochemistry and Scientific Reports.

In The Last Decade

Mark A. Varney

84 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist

1999 628 citations Mark A. Varney, Edwin C. Johnson et al. Neuropharmacology profile →

Peers

Countries citing papers authored by Mark A. Varney

Since Specialization

Citations

This map shows the geographic impact of Mark A. Varney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Varney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Varney more than expected).

Fields of papers citing papers by Mark A. Varney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Varney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Varney. The network helps show where Mark A. Varney may publish in the future.

Co-authorship network of co-authors of Mark A. Varney

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Varney. A scholar is included among the top collaborators of Mark A. Varney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Varney. Mark A. Varney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acute administration of NLX-101, a Serotonin 1A receptor agonist, improves auditory temporal processing during development in a mouse model of Fragile X Syndrome 2025 ·Journal of Neurodevelopmental Disorders ·Tao Xin, (unknown), Adrian Newman‐Tancredi, Mark A. Varney, Khaleel A. Razak	1
2	NLX-112, a highly selective 5-HT1A receptor biased agonist, does not exhibit misuse potential in male rats or macaques 2022 ·Neuropharmacology ·Ronan Depoortère, Jack Bergman, Patrick M. Beardsley, Rajeev I. Desai, Carol A. Paronis, D. Matthew Walentiny, Mark A. Varney, Adrian Newman‐Tancredi	1
3	ACNP 59th Annual Meeting: Poster Session III 2020 ·Neuropsychopharmacology ·(unknown), Mark A. Varney, (unknown), (unknown), (unknown), Steven C. Leiser, Mark O. Urban, Sarah A. Woller, (unknown), Herbert Y. Meltzer, (unknown)	3
4	Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT_1A Receptor-Biased Agonists with Robust Antidepressant-like Activity 2019 ·Journal of Medicinal Chemistry ·Joanna Śniecikowska, Monika Głuch‐Lutwin, Adam Bucki, Anna Więckowska, Agata Siwek, Magdalena Jastrzębska‐Więsek, Anna Partyka, (unknown), Karolina Pytka, Krzysztof Pociecha, (unknown), Elżbieta Wyska, Anna Wesołowska, Maciej Pawłowski, Mark A. Varney, Adrian Newman‐Tancredi, Marcin Kołaczkowski	29
5	NLX-112, a highly selective 5-HT 1A receptor agonist, mediates analgesia and antidepressant-like activity in rats via spinal cord and prefrontal cortex 5-HT 1A receptors, respectively 2018 ·Brain Research ·Adrian Newman‐Tancredi, Laurent Bardin, Agnès L. Auclair, F. C. Colpaert, Ronan Depoortère, Mark A. Varney	26
6	Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain 2017 ·Neuropharmacology ·Kinga Sałat, Marcin Kołaczkowski, Anna Furgała, (unknown), Joanna Śniecikowska, Mark A. Varney, Adrian Newman‐Tancredi	38
7	The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements 2016 ·Neuropharmacology ·Andrew C. McCreary, Mark A. Varney, Adrian Newman‐Tancredi	31
8	Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson's disease and l-DOPA-induced dyskinesia 2015 ·Neuropharmacology ·Hanna Iderberg, Andrew C. McCreary, Mark A. Varney, M. Angela Cenci, Adrian Newman‐Tancredi	57
9	Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor 2011 ·Bioorganic & Medicinal Chemistry Letters ·Liming Shao, Michael C. Hewitt, Fengjiang Wang, (unknown), Jianguo Ma, John E. Campbell, Una C. Campbell, Sharon Engel, (unknown), Larry W. Hardy, Rudy Schreiber, Kerry L. Spear, Mark A. Varney	7
10	Benzobistriazinones and related heterocyclic ring systems as potent, orally bioavailable positive allosteric AMPA receptor modulators 2011 ·Bioorganic & Medicinal Chemistry Letters ·Rudolf Mueller, Stanisław Rachwał, Mark A. Varney, Steve A. Johnson, (unknown), Sheng Zhong, Yongxin Li, Peter E. Haroldsen, (unknown), Leslie J. Street	9
11	Selective Antagonism of Opioid-Induced Ventilatory Depression by an Ampakine Molecule in Humans Without Loss of Opioid Analgesia 2009 ·Clinical Pharmacology & Therapeutics ·B. Oertel, Lisa Felden, P.V. Tran, Mark Bradshaw, Martin S. Angst, Harald Schmidt, Steve A. Johnson, John J. Greer, Gerd Geißlinger, Mark A. Varney, Jörn Lötsch	106
12	Metabotropic Glutamate Receptor mGlu5 Is a Mediator of Appetite and Energy Balance in Rats and Mice 2005 ·Journal of Pharmacology and Experimental Therapeutics ·Margaret Bradbury, Una C. Campbell, (unknown), Deborah F. Chapman, Chris King, Lida Tehrani, Nicholas D. P. Cosford, Jeff Anderson, Mark A. Varney, Alison M. Strack	75
13	Stable Expression of Human NMDA Receptors in Cultured Mammalian Cells 2003 ·Humana Press eBooks ·Mark A. Varney, Fen‐Fen Lin, Christine Jachec, Sara Rao, Stephen D. Hess, Edwin C. Johnson, Gönül Veliçelebi	4
14	Group II mGlu Receptor Activation Suppresses Norepinephrine Release in the Ventral Hippocampus and Locomotor Responses to Acute Ketamine Challenge 2003 ·Neuropsychopharmacology ·Daniel S. Lorrain, Hervé Schaffhauser, Una C. Campbell, Christopher Baccei, Lucia Correa, Blake A. Rowe, Dana E. Rodriguez, Jeffery J. Anderson, Mark A. Varney, Anthony B. Pinkerton, Jean‐Michel Vernier, Linda J. Bristow	78
15	[3H]-Methoxymethyl-MTEP and [3H]-Methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor 2003 ·Bioorganic & Medicinal Chemistry Letters ·Nicholas D. P. Cosford, Jeffrey Roppe, Lida Tehrani, Edwin J. Schweiger, T. Jon Seiders, (unknown), Sara Rao, Mark A. Varney	123
16	Metabotropic Glutamate Receptor Involvement in Models of Acute and Persistent Pain: Prospects for the Development of Novel Analgesics 2002 ·PubMed ·Mark A. Varney, (unknown)	130
17	Activation of spinal group I metabotropic glutamate receptors in rats evokes local glutamate release and spontaneous nociceptive behaviors: effects of 2-methyl-6-(phenylethynyl)-pyridine pretreatment 2002 ·Neuroscience Letters ·Daniel S. Lorrain, Lucia Correa, Jeffery J. Anderson, Mark A. Varney	31
18	[2] Fluorescence techniques for measuring ion channel activity 1999 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Gönül Veliçelebi, Kenneth A. Stauderman, Mark A. Varney, M. Akong, Stephen D. Hess, Edwin C. Johnson	23
19	The Human N‐Methyl‐d‐Aspartate Receptor 2C Subunit: Genomic Analysis, Distribution in Human Brain, and Functional Expression 1998 ·Journal of Neurochemistry ·Lorrie P. Daggett, Edwin C. Johnson, Mark A. Varney, Fen‐Fen Lin, Stephen D. Hess, C Deal, Christine Jachec, Chuanyong Lu, Julie A. Kerner, G. Bernhard Landwehrmeyer, David G. Standaert, A. B. Young, Michael M. Harpold, Gönül Veliçelebi	22
20	Inositol 1,4,5-Trisphosphate and Oxytocin Binding in Human Myometrium* 1990 ·Endocrinology ·José Rivera, A. López Bernal, Mark A. Varney, Steve P. Watson	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact